Recognizing a problem early and treatment can help avoid life-threatening complications when swelling of the larynx, or voice box, caused by hereditary angioedema (HAE) blocks the airways. That’s according to a report that describes the case of a man in China with hereditary angioedema-induced laryngeal edema (HALE), which can…
A new scoring system may help emergency physicians diagnose hereditary angioedema (HAE), potentially allowing patients to receive treatment faster, a study found. Nine HAE experts worked together to design the system, which assigns patients numerical scores based on their symptoms, family history, and responsiveness to certain treatments. “This tool…
Donidalorsen, a preventive therapy being developed to reduce the frequency of swelling attacks for people with hereditary angioedema (HAE), significantly improved quality of life and symptom control for people with the condition, a new analysis of clinical trial data suggests. Ionis Pharmaceuticals, donidalorsen’s developer, funded the study,…
Most allergist-immunologists who treat people with hereditary angioedema (HAE) think genetic testing may be useful in diagnosing irregular cases, but many say they require more education to feel confident with the specifics of testing, a study reports. “The study found that [health care providers] consider genetic testing during a…
A man in his 60s who developed severe angioedema after the use of an ACE, or angiotensin-converting enzyme, inhibitor to treat high blood pressure required several emergency interventions before making a full recovery, according to a case study from France. Swelling in the man’s throat obstructed his breathing, ultimately…
People from underrepresented racial and ethnic groups who have hereditary angioedema (HAE) continue facing barriers to diagnosis and effective care, according to a recent study. These patients reported having trouble getting adequate care before their diagnosis, and though most were satisfied with the treatment they received afterward, many…
Kaken Pharmaceutical obtained the rights to commercialize sebetralstat, an on-demand treatment for hereditary angioedema (HAE), in Japan under a licensing agreement with the HAE treatment’s developer, Kalvista Pharmaceuticals. Under the terms of the agreement, Kalvista will be eligible to receive an upfront payment of $11 million,…
Get regular updates to your inbox.
